All News

Telemedicine.MD.Computer.phone (keep)

ACR Position Statement on Telemedicine

d Jack Cush, MD

The American College of Rheumatology (ACR) has released an official position statement supporting the role of telemedicine as a tool with the potential to increase access and improve care for patients with rheumatic diseases.

Read Article
psoriasis.NPF_.png

Is IL-23 Better than IL-17 Inhibition in Psoriasis?

d Jack Cush, MD

Data presented at the recent American Academy of Dermatology meeting suggests that interleukin (IL)-23 inhibition with risankizumab was more effective than the IL-17 inhibition (secukinumab) based on a 52 week randomized head-to-head trial in moderate to severe psoriasis patients.

Read Article
covid19.logo_.jpg

Tocilizumab May Benefit COVID-19 Pneumonia

d Jack Cush, MD

A retrospective, observational study published in Lancet Rheumatology has shown that tocilizumab (TCZ) may reduce the risk of death or the need for mechanical ventilation in severe COVID-19 pneumonia. This observational study included adults, with severe COVID-19 pneumonia, who were hospitalized between Feb 21 and March 24, 2020. All were on the standard of care (ie, supplemental oxygen, hydroxychloroquine, azithromycin, antiretrovirals, and low molecular weight heparin), and a non-randomly selected subset of patients also received TCZ.

Read Article
podcast logo

RheumNow Podcast – Lupus Mortality Declines, But… (6.26.20)

d Jack Cush, MD

Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article
heart.jpg (keep)

Protective Benefit of Colchicine in COVID-19 Infection

d Jack Cush, MD

Colchicine has been advocated as a potential anti-inflammatory intervention in patients with the coronavirus 2 infection and clinical trials have been developed to assess its effect in early COVID-2 infection.  JAMA has published a randomized clinical trial showing that low dose colchicine had less clinical deterioration without significant changes in biomarkers, such as high-sensitivity cardiac troponin and C-reactive protein.

Read Article
A must watch with volume on! It is so relatable. I might adopt the same response next time I get that question "But where are you from? shortly after I said Cheshire. Even though I wasn't born here, I think spending best half of my life here qualifies the answer. https://t.co/dVdgjQl7pU

Links:

Dr Yeliz Prior #BlackLivesMatter YelizPrior ( View Tweet)

Increased rate of hospital #COVID-19 cases associated with some but not all chronic #inflammatory or #autoimmune conditions compared with reference population. The risks seem to depend on age, the specific disease and previous therapies. https://t.co/8j6R0oO99y https://t.co/n3cEXFx9Kk

Links:

ARD & RMD Open ARD_BMJ ( View Tweet)
Now with ~1,000 children and adolescents with multi-inflammatory syndrome in children (MIS-C), it can be considered a new disease. Today new @NEJM reports and an editorial on its status. I've made a summary of some key points to start https://t.co/1HSWSvumpv
Eric Topol EricTopol ( View Tweet)
The CHMP of the European Medicines Agency has recommended the label expansion of IL-17 inhibitor, Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6-18 years. https://t.co/1qYL5ASkrg

Links:

Dr. John Cush RheumNow ( View Tweet)

Fasinumab, nerve growth factor inhibitor, studied in a phase II trial of 421 moderate-to-severe OA (knee or hip) pts x36 wks & show to be better than placebo. But FAS had more AE (17% v 10%), Jt Surgeries (7% v 1%) and destructive arthropathy in 1 FAS pt https://t.co/eHvYrByF1Z

Links:

Dr. John Cush RheumNow ( View Tweet)

Truth does not belong to the one who shouts the loudest. https://t.co/QZWH5oHP6u

Links:

Dr. John Cush RheumNow ( View Tweet)

60,596 RA Medicare patients with MBDA testing showed in those not taking biologic/JAK inhibitor Rx, the odds of adding new Rx was 9.0% (with a low MBDA), 11.8% (moderate MBDA), and 19.7% (high MBDA, p < 0.0001). Higher MBDA yields more Drug switches https://t.co/Tu7jChQi06

Links:

Dr. John Cush RheumNow ( View Tweet)

Global prevalence of juvenile idiopathic arthritis is ~ 2,069,246 < 16 year olds compared with a prevalence of ~ 206,931 < 16 year olds with juvenile SLE. JIA is 10 times more prevalent than lupus in children < 16yrs. https://t.co/2xvhg59c1J

Links:

Dr. John Cush RheumNow ( View Tweet)

RECOVERY RCT, dexamethasone vs usual care in COVID19 ⬇️28d mortality in pts on O2 (21.5% vs 25%, NNT ~22) or IMV (29% vs 41%, NNT~8)... ?⬆️ for pts w/out O2 1. Preprint*️⃣ 2. No blinding, but hard outcome & meaningful benefit Will likely be adopted, kudos 🇬🇧 for a useful RCT! https://t.co/m5OAYMIvZy
Mike Putman EBRheum ( View Tweet)
If you treat #SLE patients, Do you get a renal biopsy before starting therapy for Lupus nephritis?

Dr. John Cush RheumNow ( View Tweet)

High uric acid is associated with a higher risk of kidney cancer, especially in women; Data from a UK biobank of 444 462 without cancer w/ 6.5 yrs F/U. Highest Urate quartile had increased risk of renal cancer (HR 1.45, 95%CI 1.08 to 1.93), only in women. https://t.co/APWxFkewoF

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is Up! Lupus Mortality Declines, But… Review of SUA and cancer; IL-12/23 and SLE; TCZ and Behcets, Pregnancy SI MRI, VTE w/ Jaks; COVID; Colchicine. Watch it here> https://t.co/2V7TbaAsOp or listen on iTunes or SoundCloud https://t.co/XMps2GTgeD

Links:

Dr. John Cush RheumNow ( View Tweet)

Retrospective study of 2369 patients with Kawasaki disease examined different doses of aspirin showing lower ASA doses of 20–29 mg/kg/day was as effective as 30–50 mg/kg/day in preventing coronary artery aneurysms with no change in IVIG resistance https://t.co/kJgkSSpjyw

Links:

Dr. John Cush RheumNow ( View Tweet)

J&J announced that is discontinuing its phase 3 trial of ustekinumab in #SLE. An interim analysis of the 516 pt LOTUS trial showed no new safety concerns. Study was halted for lack of efficacy. A subsequent LOTUS-C trial in China has been suspended. https://t.co/iN5trI0V71

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 1362 #RA patients given TNF inhibitors, abatacept, tocilizumab between 2011-17 finds TCZ had best survival regardless of age; ABA had lowest D/C for adverse events & disease activity improved more with TNFi. https://t.co/7RRO9M4Wf0

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×